Triterpenes are a diverse class of phytochemicals found in many medicinal plants, such as Ganoderma lucidum (Reishi mushroom), Centella asiatica, and Glycyrrhiza glabra (licorice). Their use in supporting autoimmune disorders is primarily based on preclinical and some early clinical research rather than strong tradition or widespread clinical adoption. Triterpenes have demonstrated immunomodulatory, anti-inflammatory, and antioxidant activities in vitro and in animal models relevant to autoimmune diseases like rheumatoid arthritis, multiple sclerosis, and lupus. For instance, ganoderic acids (triterpenes from Ganoderma lucidum) have been shown to downregulate pro-inflammatory cytokines and modulate T cell responses in experimental models.

However, human clinical evidence is sparse and mostly limited to small, preliminary studies or case reports. There is some indication that triterpene-rich extracts can reduce markers of inflammation or improve symptoms in autoimmune conditions, but these findings are not yet robust or widely replicated. Most research focuses on mechanisms, such as inhibition of NF-κB signaling or suppression of Th17 cell differentiation, rather than direct clinical outcomes. Thus, while there is scientific rationale and some early-stage evidence supporting the use of triterpenes for autoimmune disorders, large, high-quality clinical trials are lacking. The current evidence base justifies a cautious optimism but not strong clinical recommendations.